Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press172510.17650/1726-9776-2024-20-2-129-133CLINICAL NOTESКЛИНИЧЕСКИЕ СЛУЧАИUrachal adenocarcinoma: a rare bladder tumor managementАденокарцинома урахуса: тактика ведения редкой опухолиhttps://orcid.org/0000-0003-0980-8068PannirselvamM.PannirselvamМ.
Malaysia

Department of Surgery, School of Medical Sciences, Universti Sains Malaysia

Kubang Kerian, Kelantan, Malaysia

manivaasan.p@gmail.comDaudM. A. M.DaudM. A. М.
Malaysia

Hospital Universiti Sains Malaysia; Urology Unit, Department of Surgery, School of Medical Sciences, Universiti Sains Malaysia

Kubang Kerian, Kelantan, Malaysia

https://orcid.org/0000-0002-7674-2663OthmanM. F.OthmanМ. F.
Malaysia

Muhammad Faeid Othman 

Hospital Universiti Sains Malaysia; Urology Unit, Department of Surgery, School of Medical Sciences, Universiti Sains Malaysia

Kubang Kerian, Kelantan, Malaysia

faeid@usm.myGhaziA. F. N. M.GhaziA. F. N. М.
Malaysia

Hospital Universiti Sains Malaysia; Urology Unit, Department of Surgery, School of Medical Sciences, Universiti Sains Malaysia

Kubang Kerian, Kelantan, Malaysia

TanS. S.
Malaysia

Department of Surgery, School of Medical Sciences, Universiti Sains Malaysia

Kubang Kerian, Kelantan, Malaysia

TehG. C.
Malaysia

Department of Urology

Kuching, Sarawak, Malaysia

Universiti Sains MalaysiaHospital Universiti Sains MalaysiaSarawak General Hospital190820242021291330210202320062024https://oncourology.abvpress.ru/oncur/article/view/1725

Urachal adenocarcinoma is a rare and aggressive form of non-urothelial carcinoma. It commonly encountered the bladder at the dome or along its midline. Adenocarcinoma histology with frequent mucinous or signet ring cell features distinguishes it from traditional urothelial tumours. It usually manifests in adults aged 47 to 56, with an even distribution between genders. It constitutes about 0.5 to 2 % of all bladder malignancies. Surgery remains the primary treatment modality in prolonging patients’ overall survival time. We wish to discuss a case of a patient diagnosed with urachal adenocarcinoma.

Аденокарцинома урахуса – редкая и агрессивная форма неуротелиального рака, обычно развивающаяся на верхушке мочевого пузыря и вдоль его средней линии. В отличие от уротелиальных опухолей, данное заболевание имеет гистологическое строение аденокарциномы с муцинозными или перстневидно-клеточными характеристиками. Аденокарцинома урахуса обычно развивается у взрослых в возрасте от 47 до 56 лет с одинаковой встречаемостью среди мужчин и женщин. Аденокарцинома урахуса составляет примерно 0,5–2 % всех злокачественных новообразований мочевого пузыря. Хирургическое вмешательство остается основным методом лечения для увеличения общей выживаемости пациентов. В статье обсуждается клинический случай аденокарциномы урахуса.

urachal adenocarcinomabladder tumornon-urothelial carcinomabladder malignancyаденокарцинома урахусаопухоль мочевого пузырянеуротелиальная карциномазлокачественное новообразование мочевого пузыряBegg R.C. The urachus: its anatomy, histology and development. J Anat 1930;64(Pt 2):170–83.Scabini S., Rimini E., Romairone E. et al. Urachal tumour: case report of a poorly understood carcinoma. World J Surg Oncol [Internet] 2009 [cited 2023];7(1):1–3. Available at: https://wjso.biomedcentral.com/articles/10.1186/1477-7819-7-82Schubert G.E., Pavkovic M.B., Bethke-Bedurftig B.A. Tubular urachal remnants in adult bladders. J Urol 1982;127(1):40–2. DOI: 10.1016/s0022-5347(17)53595-8Sheldon C.A., Clayman R.V., Gonzalez R. et al. Malignant urachal lesions. J Urol 1984;131(1):1–8. DOI: 10.1016/s0022-5347(17)50167-6Pinthus J.H., Haddad R., Trachtenberg J. et al. Population based survival data on urachal tumors. J Urol 2006;175(6):2042–7. DOI: 10.1016/S0022-5347(06)00263-1Ghazizadeh M., Yamamoto S., Kurokawa K. Clinical features of urachal carcinoma in Japan: review of 157 patients. Urol Res 1983;11(5):235–8. DOI: 10.1007/BF00272286Siefker-Radtke A.O., Gee J., Shen Y. et al. Multimodality management of urachal carcinoma: the M.D. Anderson Cancer Center experience. J Urol 2003;169(4):1295–8. DOI: 10.1097/01.ju.0000054646.49381.01Molina J.R., Quevedo J.F., Furth A.F. et al. Predictors of survival from urachal cancer. Cancer 2007;110(11):2434–40. DOI: 10.1002/cncr.23070Ashley R.A., Inman B.A., Sebo T.J. et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer 2006;107(4):712–20. DOI: 10.1002/cncr.22060Siefker-Radtke A. Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther 2014;6(12):1715–21. DOI: 10.1586/14737140.6.12.1715Wong-You-Cheong J.J., Woodward P.J., Manning M.A., Sesterhenn I.A. Neoplasms of the urinary bladder: radiologicpathologic correlation. Radiographics 2006;26(2):553–80. DOI: 10.1148/rg.262055172Gopalan A., Sharp D.S., Fine S.W. et al. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol 2009;33(5):659–68. DOI: 10.1097/PAS.0b013e31819aa4aeSingh I., Prasad R. Primary urachal mucinous adenocarcinoma of the urinary bladder. J Clin Diagn Res 2013;7(5):911–3. DOI: 10.7860/JCDR/2013/5597.2973Henly D.R., Farrow G.M., Zincke H. Urachal cancer: role of conservative surgery. Urology 1993;42(6):635–9. DOI: 10.1016/0090-4295(93)90526-gHerr H.W., Bochner B.H., Sharp D. et al. Urachal carcinoma: contemporary surgical outcomes. J Urol 2007;178(1):74–8. DOI: 10.1016/j.juro.2007.03.022Elser C., Sweet J., Cheran S.K. et al. A case of metastatic urachal adenocarcinoma treated with several different chemotherapeutic regimens. Can Urol Assoc J 2012;6(1):E27–31. DOI: 10.5489/cuaj.11109